The effect of some decarboxylase inhibitors on striatal tyramines in the mouse.
The administration of carbidopa (5-50 mg/kg), a peripheral L-aromatic aminoacid decarboxylase inhibitor, significantly increased striatal tyramines; maximal effects were observed at 2-4 hr after treatment. Benserazide produced similar effects. The drug, NSD 1034, that inhibits both central and peripheral decarboxylase, produced a dose-dependent reduction in striatal p-tyramine; in contrast, concentrations of m-tyramine were increased by the smaller doses (2-20 mg/kg) and reduced by the larger dose (400 mg/kg). The results support the view that the tyramines are formed within the brain by decarboxylation of their parent aminoacids but by different mechanisms.[1]References
- The effect of some decarboxylase inhibitors on striatal tyramines in the mouse. Juorio, A.V. Neuropharmacology (1983) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
